跳至主要内容
临床试验/NCT02281669
NCT02281669Unknown不适用

Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients

Sheba Medical Center1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Adverse effects

研究概览

简要总结

Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local treatment available is intralesional (IL) Pentostam injection. During the current study the investigators will monitor the adverse effects of this treatment and will follow up the recovery of the lesions after Pentostam injections.

详细描述

Cutaneous leishmaniasis is usually treated by topical intervention. In more severe cases intralesional Pentostam injection may be applied. This treatment is extremely efficient but painful, however without the known adverse effects of IV Pentostam treatment.

In this study the investigators will follow systematically all leishmania patients who are receiving the intralesional treatment. A structured questionnaire will be filled up in each doctor visit.

The current study goal is to examine the adverse effects and the patient reaction to this treatment, and to follow the recovery of lesion(s) after this treatment including the number of IL injections which was needed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cutaneous leishmaniasis patients
  • Treatment by IL Pentostam
  • Age above 18 years

排除标准

  • Children and pregnant women will not participate in the study

研究组 & 干预措施

Research group

The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].

干预措施: Pentostam (Drug)

结局指标

主要结局

Adverse effects

时间窗: 1 year

The adverse effects of IL Pentostam treatment will be monitored during the follow up period.

次要结局

  • Lesion healing(1 year)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Eli Schwartz MD, DTMH

Principal investigator of the geographic clinic, Sheba medical center

Sheba Medical Center

研究点 (1)

Loading locations...

相似试验